Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.63 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10712165 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL2584388 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL20556461 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL3117366 | 0.93 | CASP2 (0.54) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL4068490 | 0.88 | CASP2 (0.71) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL9548566 | 0.86 | CASP2 (0.75) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL13925083 | 0.86 | CASP2 (0.68) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL14890990 | 0.86 | CASP2 (0.75) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL14370358 | 0.86 | CASP2 (0.75) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL11923736 | 0.86 | CASP2 (0.75) | CASP2NAAAEPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023112033-A2 | COMPOUNDS USEFUL FOR THE PREPARATION OF VARIOUS AGROCHEMICALS AND MARKERS THEREOF | ADAMA AGAN LTD. (IL) | 2023-06-22 | — | — | WO | disclosed |
| US-11560367-B2 | Pyrrolidinones and a process to prepare them | FMC CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210107890-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-10875838-B2 | Pyrrolidinones and a process to prepare them | FMC CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3599854-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC Corporation (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3230264-B1 | 3-OXO-3-(ARYLAMINO)PROPANOATES, A PROCESS FOR THEIR PREPARATION, AND THEIR USE IN PREPARING PYRROLIDINONES | FMC CORP (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10227286-B2 | 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones | FMC CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227286-B2 | 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones | FMC CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2018175226-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC CORPORATION (US) | 2018-09-27 | — | — | WO | disclosed |
| US-20180057442-A1 | 3-OXO-3-(ARYLAMINO)PROPANOATES, A PROCESS FOR THEIR PREPARATION, AND THEIR USE IN PREPARING PYRROLIDINONES | FMC CORPORATION | 2018-03-01 | — | — | US | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-7482488-B2 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1539675-A4 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060167317-A1 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1539675-A2 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004037751-A2 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2004-05-06 | — | — | WO | disclosed |
| US-4735962-A | ANTICOAGULANTS, BRONCHODILATORS | E. R. SQUIBB & SONS, INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4654356-A | BRONCHODILATORS, ANTIASTHMA, THROMBOSIS ANTICOAGULANTS | E. R. SQUIBB & SONS, INC. (US) | 1987-03-31 | — | — | US | disclosed |
| EP-0210664-A2 | 7-oxabicycloheptane substituted diacid diamide prostaglandin analogs | E.R. Squibb & Sons, Inc. (US) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227286-B2 | 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones | SDHA, SDHB, NDUFV3 | CASP2 3354/4885NAAA 2209/4885EPHX1 1361/4885 |
| US-20060167317-A1 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | BCL2A1, NFE2L2, BCL2 | CASP2 138/4885NAAA 2770/4885EPHX1 2517/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | CASP2 3337/4885NAAA 1455/4885EPHX1 1408/4885 |
| US-10875838-B2 | Pyrrolidinones and a process to prepare them | CCNB1, CCNA2, F2 | CASP2 2602/4885NAAA 1933/4885EPHX1 1765/4885 |
| US-20210107890-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | CCNB1, CCNA2, F2 | CASP2 2602/4885NAAA 1933/4885EPHX1 1765/4885 |
| US-11560367-B2 | Pyrrolidinones and a process to prepare them | CCNB1, CCNA2, F2 | CASP2 2602/4885NAAA 1933/4885EPHX1 1765/4885 |
| US-20180057442-A1 | 3-OXO-3-(ARYLAMINO)PROPANOATES, A PROCESS FOR THEIR PREPARATION, AND THEIR USE IN PREPARING PYRROLIDINONES | SDHA, SDHB, NDUFV3 | CASP2 3354/4885NAAA 2209/4885EPHX1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.